Letter

POPADAD trial

Don’t stop taking aspirin

BMJ 2008; 337 doi: 10.1136/bmj.a2581 (Published 19 November 2008)
Cite this as: BMJ 2008;337:a2581

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Peter Elwood, honorary professor1
  1. 1School of Medicine, Cardiff University, Cardiff CF14 4XN
  1. elwood{at}doctors.org.uk

    The POPADAD trial shows no benefit from daily prophylactic aspirin (hazard ratio 0.98; P=0.87) in people who have diabetes and early peripheral arterial disease. However, no firm conclusions should be drawn from a single trial, but the result be incorporated in a meta-analysis of all available evidence from relevant trials.1

    The absence of evidence of benefit is not surprising as the trial was seriously underpowered. The annual …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular